Nuvelo to Present at the UBS Warburg Global Life Sciences Conference
Thursday September 18, 9:30 am ET
SUNNYVALE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nuvelo today announced that Dr. Ted W. Love, president and CEO, will be presenting at the UBS Warburg Global Life Sciences Conference on Thursday, September 25, 2003 at 8:00 a.m. Eastern Time at The Plaza Hotel in New York City.
Dr. Love will provide a brief corporate overview and discuss the company's near-term milestones, including an update on the status of its two Phase II clinical trials with lead product candidate, alfimeprase.
A live audio webcast of the presentation will be available online on the UBS homepage at www.ibb.ubs.com. To access the webcast, click on the Conferences section and follow the link for the webcast under the Global Life Sciences Conference heading. You can also access the webcast via the Investor Relations portion of the Nuvelo Web site at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc., formed by the merger of Hyseq Pharmaceuticals, Inc. and VARIAGENICS, Inc., is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's lead product candidate, alfimeprase, is partnered with Amgen and is currently in two Phase II trials in two indications, peripheral arterial occlusion and catheter occlusion. Additional programs include drug discovery focused on antibody targets and secreted proteins.
Information about Nuvelo is available at our new Web site at www.nuvelo.com or by phoning 408-215-4000.
Source: Nuvelo, Inc. |
